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Background. Most evidence regarding anticoagulation and COVID-19 refers to the hospitalization setting, but the role of oral
anticoagulation (OAC) before hospital admission has not been well explored. We compared clinical outcomes and short-term
prognosis between patients with and without prior OAC therapy who were hospitalized for COVID-19. Methods. Analysis of the
whole cohort of the HOPE COVID-19 Registry which included patients discharged (deceased or alive) after hospital admission for
COVID-19 in 9 countries. All-cause mortality was the primary endpoint. Study outcomes were compared after adjusting variables
using propensity score matching (PSM) analyses. Results. 7698 patients were suitable for the present analysis (675 (8.8%) on OAC
at admission: 427 (5.6%) on VKAs and 248 (3.2%) on DOACs). After PSM, 1276 patients were analyzed (638 with OAC; 638
without OAC), without signiﬁcant diﬀerences regarding the risk of thromboembolic events (OR 1.11, 95% CI 0.59–2.08). The risk
of clinically relevant bleeding (OR 3.04, 95% CI 1.92–4.83), as well as the risk of mortality (HR 1.22, 95% CI 1.01–1.47; log-rank p
value � 0.041), was signiﬁcantly increased in previous OAC users. Amongst patients on prior OAC only, there were no diﬀerences
in the risk of clinically relevant bleeding, thromboembolic events, or mortality when comparing previous VKA or DOAC users,
after PSM. Conclusion. Hospitalized COVID-19 patients on prior OAC therapy had a higher risk of mortality and worse clinical
outcomes compared to patients without prior OAC therapy, even after adjusting for comorbidities using a PSM. There were no
diﬀerences in clinical outcomes in patients previously taking VKAs or DOACs. This trial is registered with NCT04334291/
EUPAS34399.

1. Introduction
Vascular inﬂammation, hypercoagulable state, and endothelial dysfunction have been described in patients with
severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) infection [1, 2]. As a result, thromboembolic
complications are common in patients with coronavirus
disease 2019 (COVID-19) [3–5]. Therefore, antithrombotic
therapy, particularly anticoagulation, gained attention in the
context of COVID-19. Indeed, some studies demonstrated
that anticoagulation may be associated with improved
outcomes among patients with COVID-19 [6, 7]. However,
most of the evidence in relation to anticoagulation and
COVID-19 refer to the acute hospitalization setting, whereas
the role of stable oral anticoagulation (OAC) therapy before
the admission for COVID-19 has not been well explored.
One study suggested a protective role of chronic directacting OAC (DOAC) therapy in elderly patients with
COVID-19 [8]. In a preliminary analysis of the International
COVID-19 Clinical Evaluation (HOPE COVID-19) Registry
published previously, we observed that COVID-19 patients
on OAC therapy at hospital admission had lower survival
and higher mortality risk compared to patients without prior
OAC [9].
In the present study, we aimed to compare clinical
outcomes and in-hospital prognosis between patients on
prior OAC therapy and patients not on OAC therapy who
were admitted for COVID-19 and enrolled in the HOPE
COVID-19 Registry, using a propensity score matching
(PSM) approach. Second, we aimed to compare clinical
outcomes and prognosis between patients on vitamin K

antagonist (VKA) therapy and patients on DOACs before
admission.

2. Methods
A detailed description of the HOPE COVID-19 Registry has
been published elsewhere [10, 11]. Brieﬂy, the HOPE
COVID-19 is an ambispective international registry, real-life
cohort “all comers” type, including more than 8100 patients
from 9 countries (Canada, China, Chile, Colombia, Cuba,
Ecuador, Germany, Italy, and Spain). The study was an
initiative without conﬂicts of interest, no ﬁnancial remuneration, and methodological support from the Institute for
the Improvement of Health Care (IMAS) foundation
(Madrid, Spain).
All patients discharged (deceased or alive) after hospital
admissions for COVID-19 were suitable for the study. There
were no exclusion criteria, except for patients’ explicit refusal
to participate. The ﬁrst patient was included in February
2020. Clinical and demographic data were collected at inclusion and during the hospitalization in an anonymized
database presented in the electronic format, to be ﬁlled in at
each participating center (NCT04334291/EUPAS34399).
Reporting of the study conforms to broad EQUATOR
guidelines. The study was performed according to the ethical
principles of Declaration of Helsinki and Good Clinical
Practice Guidelines and has been approved by Ethics Research Committee from the Hospital Clı́nico San Carlos
(Madrid, Spain) (20/241-E) and the Spanish Agency for
Medicines and Health Products (EPA-0D). Given the
anonymous characteristics of the registry and the health
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alarm situation generated by the virus, in principle, written
informed consent was waived. However, at least verbal
authorization from the patient (or familiar or caregiver,
when unavailable) was required.
2.1. Laboratory Analyses. Laboratory parameters were
considered elevated as deﬁned by local laboratory cutoﬀ
levels. However, the HOPE COVID-19 Registry protocol
suggested the following as “elevated:” for D-dimer (≥0.5 mg/
L), for procalcitonin (≥0.5 ng/mL), for C-reactive protein
(≥10 mg/L), for troponins (>99th percentile), for transaminases (≥40 U/L), for ferritin (≥336 ng/mL), and for lactate
dehydrogenase (≥280 U/L).
2.2. Study Outcomes. The primary endpoint for this analysis
was in-hospital all-cause mortality. Any thrombotic/
thromboembolic event and any clinically relevant bleeding
were the secondary outcomes. Bleeding was deﬁned as
“relevant” at the discretion of the attending medical team
and classiﬁed using the BARC bleeding score as type 2, 3, or
5.
Although not classiﬁed as primary or secondary outcomes, other adverse events during hospitalization were
recorded, including renal failure, respiratory insuﬃciency,
upper respiratory tract infection, heart failure, sepsis, and
systemic inﬂammatory response syndrome (SIRS).
Local researchers identiﬁed, conﬁrmed, and recorded all
adverse events. The clinical management was decided, in all
cases, by the attending team and researchers had no role in
this point.
2.3. Statistical Analysis. Quantitative variables were
expressed as mean ± standard deviation (SD) or median and
interquartile range (IQR), as appropriate according to the
Kolmogorov–Smirnov test, whilst categorical variables were
expressed as absolute frequencies and percentages. Pearson’s
chi-squared test was used to compare proportions. Diﬀerences between two groups regarding a quantitative variable
were tested with Student’s t or the Mann–Whitney U tests, as
appropriate if normally or not normally distributed.
To compare the risk of the study outcomes among patients on prior OAC therapy and patients without prior
OAC therapy, we conducted a propensity score matching
(PSM) adjusting for demographics and baseline comorbidities. The risk of the study outcomes among patients on
prior VKA therapy or DOACs was also evaluated by another
PSM. In both PSMs, those variables that were signiﬁcantly
diﬀerent between both cohorts were included in the model
to adjust for diﬀerences. Patients were matched 1 : 1 across
each cohort on a propensity score generated by logistic
regressions using the nearest neighbour technique without
replacement with a maximum caliper of 0.2, thus avoiding at
least 98% of the bias due to the measured confounders. The
value of absolute standardized mean diﬀerence <10% indicated balance of matched cohorts [12, 13].
Survival analyses by Kaplan–Meier estimates were
performed after PSM to assess diﬀerences in event-free
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survival of the primary outcome depending on the use (or
not) of prior OAC therapy and depending on the use of prior
VKA or DOAC therapy. The risk of suﬀering from the
primary outcome was assessed by Cox proportional hazard
regression, and results were reported as hazard ratio (HR)
with 95% conﬁdence interval (CI). The risk of suﬀering from
other study outcomes was investigated by logistic regression
analyses, since the exact date for these events was not
recorded. In these analyses, results were reported as odds
ratio (OR) with 95% conﬁdence interval (CI).
Two-sided p values <0.05 were accepted as statistically
signiﬁcant. Statistical analyses were performed using SPSS v.
24.0 (SPSS, Inc., Chicago, IL, USA) and MedCalc v. 16.4.3
(MedCalc Software bvba, Ostend, Belgium) for Windows.

3. Results
A cohort of 8168 patients was included. After excluding
patients with insuﬃcient or not reliable data on previous
OAC, 7698 patients remained in the study (4500 (58.5%)
male; median age of 65 (IQR 51–77) years). Of these, 675
(8.8%) were on OAC therapy at hospital admission, 427
(5.6%) were on VKAs, and 248 (3.2%) were on DOACs.
3.1. Outcomes on Prior OAC Therapy. In the overall cohort of
7698 patients, we found that patients on prior OAC therapy
were less commonly admitted in the intensive care unit
(ICU) compared to patients not previously taking OACs
(6.7% vs. 10.1%, p � 0.004). During hospitalization, the
prognosis of patients on prior OAC therapy was also poor,
and these patients had more incident heart failure, renal
failure, sepsis, and SIRS (all with p value <0.001). As expected, the risk of any clinically relevant bleeding in patients
with previous OAC therapy was higher compared to patients
not taking OAC previously (11.6% vs. 3.4%, p < 0.001; OR
3.71, 95% CI 2.83–4.85), without diﬀerences in terms of
thromboembolic events (3.1% vs. 2.7%, p � 0.493). The risk
of mortality was found to be signiﬁcantly increased in patients on prior OAC therapy (39.1% vs. 17.0%, p < 0.001; HR
2.45, 95% CI 2.14–2.79); however, there were signiﬁcant
diﬀerences between patients on prior and not on prior OAC
in terms of several comorbidities. We therefore performed
PSM to adjust these analyses (Table 1).
After PSM, 1276 patients remained in the study (638 :
638 paired comparisons), with no signiﬁcant diﬀerences
regarding admission to the ICU in patients on prior OAC
compared to patients not previously taking OACs (6.9% vs.
6.3%, p � 0.652). The prognosis of patients on prior OAC
therapy during hospitalization was still poor even after
adjustment, and these patients suﬀered more commonly
from heart failure, renal failure, and SIRS (all with p value
<0.05). No signiﬁcant diﬀerences were found in terms of
respiratory insuﬃciency (67.2% vs. 64.7%; p � 0.280), upper
respiratory tract infection (13.9% vs. 14.1%; p � 0.987), or
sepsis (15.0% vs. 12.1%; p � 0.299) (Table 2).
Similar to the ﬁnding observed before PSM, the risk of
any clinically relevant bleeding was higher in patients with
previous OAC therapy compared to patients not taking
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Table 1: Comparison of clinical characteristics of the study cohort before and after propensity score matching.
Before propensity score matching
Patients without
Patients with prior
P
prior OAC
OAC
value
N � 7023
N � 675

Demographic
Male sex, n (%)
4097 (58.3)
Age (years), median (IQR)
63 (50–75)
Race (non-Caucasian), n (%)
1603 (22.8)
Body mass index (kg/m2),
27.1 (24.2–30.7)
median (IQR)
Baseline comorbidities, n (%)
Hypertension
3176 (45.2)
Diabetes mellitus
1257 (17.9)
Heart failure
128 (1.8)
Stroke/TIA
439 (6.3)
Chronic kidney disease
369 (5.3)
Vascular disease∗
543 (7.7)
Hypercholesterolemia
2096 (29.8)
Current smoking habit
407 (5.8)
COPD/SAHS
419 (6.0)
History of malignant disease
822 (11.7)
Liver disease
238 (3.4)
Dysthyroidism
334 (4.8)
Any dependency level
819 (11.7)
Concomitant treatment at admission, n (%)
Beta-blockers
865 (12.3)
ACEi/ARBs
2320 (33.0)
Antiplatelet therapy
1229 (17.5)
Laboratory parameters at admission
Creatinine (mg/dL), median
0.90 (0.72–1.17)
(IQR)
Hemoglobin (g/dL), median
14.0 (12.0–15.0)
(IQR)
9
Platelet count (×10 /L),
203.0 (155.0–265.8)
median (IQR)
Elevated D-dimer, n (%)
3921 (55.8)
Elevated procalcitonin, n (%)
1048 (14.9)
Elevated C-reactive protein, n
5841 (83.2)
(%)
Elevated troponins, n (%)
527 (7.5)
Elevated transaminases, n (%)
2598 (37.0)
Elevated ferritin, n (%)
2306 (32.8)
Elevated lactate
4414 (62.9)
dehydrogenase, n (%)

After propensity score matching
Patients without
Patients with prior
prior OAC
OAC
N � 638
N � 638

P
value

403 (59.7)
80 (72–86)
59 (8.7)

0.491
<0.001
<0.001

386 (60.5)
80 (72–86)
49 (7.7)

372 (58.3)
80 (72–86)
59 (9.2)

0.425
1.000
0.315

27.7 (25.0–31.2)

0.011

26.9 (24.5–30.5)

26.7 (25.0–31.3)

0.168

542 (80.3)
198 (29.3)
46 (6.8)
131 (19.4)
115 (17.0)
102 (15.1)
344 (51.0)
35 (5.2)
104 (15.4)
139 (20.6)
33 (4.9)
40 (5.9)
210 (31.1)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.243
<0.001
<0.001
0.001
0.177
<0.001

433 (68.0)
168 (27.0)
35 (5.5)
92 (14.4)
69 (11.0)
93 (14.6)
288 (45.1)
21 (3.3)
81 (12.7)
129 (20.2)
30 (4.7)
37 (5.8)
177 (28.2)

516 (80.9)
190 (30.3)
39 (6.1)
122 (19.1)
109 (17.0)
88 (13.8)
326 (51.1)
31 (4.9)
84 (13.2)
129 (20.2)
31 (4.9)
40 (6.3)
194 (30.6)

0.053
0.198
0.632
0.437
0.487
0.688
0.085
0.071
0.802
1.000
0.795
0.724
0.365

328 (48.6)
369 (54.7)
74 (11.0)

<0.001
<0.001
<0.001

132 (20.7)
311 (48.7)
199 (31.2)

311 (48.7)
350 (54.9)
72 (11.3)

<0.001
0.086
<0.001

1.19 (0.90–1.64)

<0.001

0.98 (0.78–1.42)

1.20 (0.88–1.66)

<0.001

13.0 (11.0–14.0)

<0.001

13.0 (12.0–15.0)

13.0 (11.0–14.0)

<0.001

179.0
(136.0–240.0)
358 (53.0)
126 (18.7)

<0.001 195.0 (145.0–260.8) 181.0 (138.0–241.0)

0.019

0.036
0.001

425 (66.6)
103 (16.1)

342 (53.6)
123 (19.3)

<0.001
0.299

608 (90.1)

<0.001

566 (88.7)

576 (90.3)

0.657

107 (15.9)
220 (32.6)
207 (30.7)

<0.001
0.009
0.424

54 (8.5)
216 (33.9)
198 (31.0)

100 (15.7)
210 (32.9)
198 (31.0)

<0.001
0.023
1.000

464 (68.7)

0.005

427 (66.9)

440 (69.0)

0.466

ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; IQR, interquartile range; TIA, transient ischemic attack; COPD/
SAHS, chronic obstructive pulmonary disease/sleep apnea-hypopnea syndrome. ∗ Coronary artery disease and/or peripheral artery disease.

OAC previously (11.4% vs. 4.1%, p < 0.001; OR 3.04, 95% CI
1.92–4.83), without diﬀerences in the risk of thromboembolic events (3.3% vs. 3.0%, p � 0.748; OR 1.11, 95% CI
0.59–2.08). There was increased mortality in patients who
were on previous OAC therapy in comparison to patients
who were not on previous OAC (38.1% vs. 30.9%,
p � 0.007), with a signiﬁcantly higher risk of death (HR 1.22,
95% CI 1.01–1.47), also conﬁrmed by the Kaplan–Meier
analysis (log-rank p value � 0.041) (Figure 1). There were no
diﬀerences between patients on prior or non-prior OAC
therapy regarding speciﬁc causes of death (cardiovascular
death: 2.6% vs. 2.5%; respiratory-related: 59.7% vs. 62.9%;

SIRS-related: 4.9% vs. 3.6%; sepsis-related: 3.3% vs. 7.6%;
other reasons or combined causes of death: 29.6% vs. 23.4%;
p � 0.187).
3.2. Impact of OAC Type. In patients on prior OAC therapy,
we observed signiﬁcant diﬀerences regarding age and
comorbid conditions between patients who were previously
taking VKAs and those who were on prior DOAC therapy. We
performed another PSM to balance these characteristics. This
analysis demonstrated no diﬀerences in the remaining 464
subjects: 232 on VKAs and 232 on DOACs, as given in Table 3.
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Table 2: Clinical outcomes during hospitalization after propensity score matching.
Patients without prior OAC (N � 638)
Incidence per 100 patientsN (%)
days (95% CI)
Intensive care unit admission

40 (6.3)

0.52 (0.37–0.71)

151
(23.7)
413
(64.7)
90
(14.1)
65
(10.2)
77
(12.1)
129
(20.2)
197
(30.9)

Renal failure
Respiratory insuﬃciency
Upper respiratory tract
infection
Heart failure
Sepsis
Systemic inﬂammatory
response syndrome
All-cause mortality
Any thrombotic/
thromboembolic event

1.97 (1.67–2.31)
5.39 (4.89–5.94)
1.18 (0.95–1.44)
0.85 (0.66–1.08)
1.01 (0.79–1.26)
1.69 (1.41–2.00)
2.57 (2.23–2.96)
0.25 (0.15–0.39)

Any clinically relevant bleeding 26 (4.1)

0.34 (0.22–0.50)

Event-Free Survival (%)

19 (3.0)

100
90
80
70
60
50
40
30
20

Patients with prior OAC (N � 638)
P
Incidence per 100 patients- OR (95% CI) value
N (%)
days (95% CI)
1.11
0.652
44 (6.9)
0.58 (0.42–0.77)
(0.71–1.73)
1.61
212
0.001
2.77 (2.41–3.17)
(1.26–2.06)
(33.2)
1.09
429
0.280
5.60 (5.09–6.16)
(0.86–1.38)
(67.2)
0.99
89
0.987
1.16 (0.93–1.43)
(0.72–1.35)
(13.9)
1.93
115
<0.001
1.50 (1.24–1.80)
(1.39–2.68)
(18.0)
1.29
96
0.299
1.25 (1.02–1.53)
(0.93–1.78)
(15.0)
1.55
181
0.003
2.36 (2.03–2.73)
(1.20–2.02)
(28.4)
1.38
243
0.007
3.17 (2.79–3.60)
(1.09–1.74)
(38.1)
1.11
0.748
21 (3.3)
0.27 (0.17–0.42)
(0.59–2.08)
3.04
73
<0.001
0.96 (0.75–1.20)
(1.92–4.83)
(11.4)

p � 0.703), with a non-signiﬁcant diﬀerence in mortality
risk amongst previous VKA users (HR 0.84, 95% CI
0.62–1.12; p � 0.233) (Figure 2).

Log-rank test p-value = 0.041
0

Number at risk
Non-prior OAC 638
Prior OAC 638

10

20

30
40
Time (days)

50

60

70

341
336

176
185

83
114

25
42

12
21

7
15

43
71

Non-prior OAC
Prior OAC

Figure 1: Comparison of survival curves between patients on prior
OAC and nonprior OAC. Solid line, nonprior OAC; dashed line,
prior OAC.

With this matched cohort, the rate of ICU admission
between patients on VKAs (14, 6.0%) and patients on
DOACs (14, 6.0%) was similar (p � 1.000). There were no
diﬀerences in terms of respiratory insuﬃciency, heart failure, development of renal failure, upper respiratory tract
infection, sepsis, or SIRS, in patients on prior VKAs or
DOACs (all p > 0.005) (Supplementary Table 1).
No signiﬁcant diﬀerences in the incidences of clinically
relevant bleeding or thromboembolic events were observed
in patients previously taking VKAs compared to DOACs
(1.01 vs. 0.83 per 100 patient-days (p � 0.458) and 0.29 vs.
0.11 per 100 patient-days (p � 0.127), respectively) (Supplementary Table 1). Mortality rate between previous VKA
and DOAC users was also similar (37.9% vs. 39.7%,

3.3. Anticoagulation Management during Hospitalization.
Regarding anticoagulation during hospitalization in the
PSM cohort of previous vs. no previous OAC, most patients
not taking OAC previously were prescribed heparin (79.9%,
382/478) and 19.2% (92/478) did not receive anticoagulation. In patients who were previously on OAC, 65.5%
(330/504) were switched to heparin, 25% (126/504) continued on OAC, and 9.5% (48/504) did not receive any
anticoagulation therapy. These proportions were signiﬁcantly diﬀerent (p < 0.001).
In the PSM cohort of previous VKA vs. DOAC, most
patients under either therapy received heparin during
hospitalization, without diﬀerences between drug families
(116 vs. 114; p � 0.567). Those patients who were maintained
on OAC during admission were predominately treated with
the same OAC that they were before (95.5% for previous
VKAs users and 93.2% for previous DOACs users;
p < 0.001).

4. Discussion
In this study of the HOPE COVID-19 Registry, including a
large cohort of patients hospitalized for COVID-19, we
demonstrate that the risk of in-hospital worse clinical
outcomes was higher in patients with prior OAC therapy,
even after adjustment by a PSM. Importantly, this study
population showed a 22% higher risk of mortality and
bleeding, without signiﬁcant diﬀerences in the prognosis
with regard to the particular anticoagulant drug, i.e., VKAs
versus DOACs.
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Table 3: Comparison of clinical characteristics of patients on VKA or DOAC prior admission after propensity score matching.
Patients on prior VKA
N � 232

Patients on prior DOAC
N � 232

P value

139 (59.9)
80 (72–87)
28.0 (25.1–31.6)

127 (54.7)
81 (73–86)
27.3 (24.3–31.0)

0.260
0.575
0.445

189 (81.5)
61 (26.3)
15 (6.5)
42 (18.1)
31 (13.4)
33 (14.2)
112 (48.3)
13 (5.6)
30 (12.9)
38 (16.4)
18 (7.8)
68 (29.3)

178 (76.7)
74 (31.9)
14 (6.0)
47 (20.3)
31 (13.4)
34 (14.7)
113 (48.7)
9 (3.9)
29 (12.5)
38 (16.4)
17 (7.3)
72 (31.0)

0.209
0.184
0.848
0.555
1.000
0.895
0.926
0.143
0.889
1.000
0.860
0.686

103 (44.4)
130 (56.0)
24 (10.3)

124 (53.4)
123 (53.0)
27 (11.6)

0.042
0.703
0.656

1.19 (0.87–1.56)
13.0 (12.0–14.0)
178.0 (138.0–244.8)
121 (52.2)
45 (19.4)
209 (90.1)
35 (15.1)
86 (37.1)
75 (32.3)
167 (72.0)

1.13 (0.87–1.56)
13.0 (11.0–14.0)
176.0 (134.0–233.0)
118 (50.9)
40 (17.2)
210 (90.5)
31 (13.4)
66 (28.4)
61 (26.3)
150 (64.7)

0.628
0.853
0.432
0.954
0.795
0.984
0.711
0.138
0.344
0.182

Demographic
Male sex, n (%)
Age (years), median (IQR)
Body mass index (kg/m2), median (IQR)
Baseline comorbidities, n (%)
Hypertension
Diabetes mellitus
Heart failure
Stroke/TIA
Chronic kidney disease
Vascular disease∗
Hypercholesterolemia
Current smoking habit
COPD/SAHS
History of malignant disease
Dysthyroidism
Any dependency level
Concomitant treatment at admission, n (%)
Beta-blockers
ACEi/ARBs
Antiplatelet therapy
Laboratory parameters at admission
Creatinine (mg/dL), median (IQR)
Hemoglobin (g/dL), median (IQR)
Platelet count (×109/L), median (IQR)
Elevated D-dimer, n (%)
Elevated procalcitonin, n (%)
Elevated C-reactive protein, n (%)
Elevated troponins, n (%)
Elevated transaminases, n (%)
Elevated ferritin, n (%)
Elevated lactate dehydrogenase, n (%)

Event-Free Survival (%)

ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; IQR, interquartile range; TIA, transient ischemic attack; COPD/
SAHS, chronic obstructive pulmonary disease/sleep apnea-hypopnea syndrome. ∗ Coronary artery disease and/or peripheral artery disease.

100
90
80
70
60
50
40
30
20

Log-rank test p-value = 0.225
0

Number at risk
Prior DOAC use 232
Prior VKA use 232

10

20

107
128

50
75

30
40
Time (days)
28
50

14
33

50

60

70

6
22

3
12

1
9

Prior VKA use
Prior DOAC use

Figure 2: Comparison of survival curves between patients on prior
VKAs or DOACs. Solid line, prior VKA use; dashed line, prior
DOAC use.

Anticoagulation in the context of COVID-19 has been
widely debated, with some studies showing that prophylactic
and therapeutic anticoagulation might reduce mortality in

hospitalized COVID-19 patients [14]. Patients who received
high-intensity prophylactic anticoagulation have a downtrend in D-dimer levels and improved 30-day mortality [15].
Indeed, a cross-sectional analysis showed that anticoagulation use was associated with delayed death, both at
prophylactic (HR 0.29, 95% CI 0.15–0.58; p < 0.001) and
therapeutic doses (HR 0.15, 95% CI 0.07–0.32; p < 0.001),
compared with no anticoagulation [16]. In contrast, one
retrospective analysis of hospitalized COVID-19 patients
suggested that therapeutic anticoagulation provided no
mortality beneﬁt over thromboprophylaxis, independently
of comorbidities or disease severity, and more adverse events
were observed with therapeutic anticoagulation [17]. On the
other hand, a large cohort study simulating an intention-totreat clinical trial analyzed the eﬀect on mortality of anticoagulation therapy chosen in the ﬁrst 48 hours of hospitalization showing that patients with moderate or severe
illness beneﬁted from anticoagulation and that apixaban had
a similar eﬃcacy to enoxaparin in decreasing mortality
amongst these patients [18]. Another study showed that
hospitalized COVID-19 patients suﬀered from more
bleeding events in those on low-molecular-weight heparin
(LMWH) compared to DOACs, and DOAC use may be
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associated with better survival and lower invasive respiratory
support rate compared to LMWH [19]. Given such contradictory observations, there are a number of studies and
clinical trials with the aim to assess the role of antithrombotic therapy on mortality and thromboembolic events
[20–26].
OAC management in the setting of the COVID-19
pandemic is even more complex. VKAs have the limitation
of routine monitoring and dose adjusting for maintaining
good quality of anticoagulation. One study demonstrated a
signiﬁcant increase in high INR results during the COVID19 pandemic, the majority of them after the introduction of a
lockdown [27]. In addition, patients on VKA hospitalized
with SARS-CoV-2 showed greater instability of PT INR due
to the inﬂammatory state and the interactions with numerous drugs. On the other hand, DOACs avoid some of the
VKA limitations, but DOAC-treated patients have an increase in DOAC plasma levels when treated with antiviral
drugs for COVID-19 [28]. For these reasons, some groups
have suggested replacing OAC with parenteral heparin
during hospitalization to avoid the risk of over/under
treatment [29, 30]. Nevertheless, other authors suggested
that the indications for antiplatelet/anticoagulant use
(prevention, prophylaxis, and therapy) should be guided by
the clinical context and the COVID-19 severity and not
based on a systematic change per protocol in all patients
[31, 32].
Nevertheless, most of the evidence focused on hospitalized patients, whereas the potential eﬀect of chronic
antithrombotic therapies in COVID-19 progression and
prognosis remains uncertain. The pathophysiology underlying the prothrombotic state elicited by SARS-CoV-2
outlines possible protective mechanisms of antithrombotic
therapy for this viral disease. In particular, aspirin and FXa
inhibitors have been postulated as potential prophylactic
and therapeutic treatment for high-risk patients with
COVID-19 [31, 33]. Unsurprisingly, ongoing clinical trials
are comparing the eﬀectiveness and safety of apixaban,
aspirin, and rivaroxaban versus heparin, placebo, and other
therapies on progression, arterial, and venous thromboembolic events and mortality in patients with COVID-19
not yet admitted to hospital [34–36].
To date, data in this particular context are scarce and
limited, with positive, negative, and neutral results. One
small study in an Italian cohort of elderly patients with
COVID-19 concluded that chronic DOAC intake was an
independent parameter associated with a decreased mortality risk (HR 0.38, 95% CI 0.17–0.58; p � 0.010) [8].
Similarly, another study in Italy showed that elderly patients
with COVID-19 on chronic OAC treatment for atrial ﬁbrillation had lower all-cause mortality rate ratio compared
to their PSM non-anticoagulated counterpart [37]. However,
Sivaloganathan et al. demonstrated that patients taking
antithrombotic therapy (anticoagulant or antiplatelet
agents) at the time of infection with COVID-19 did not have
a signiﬁcantly diﬀerent mortality risk to those patients not
taking these drugs [38]. Another study showed no diﬀerence
in the risk of acute respiratory distress syndrome at admission or death during hospitalization between COVID-19
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patients treated or not with antiplatelets or anticoagulants
preadmission [39]. Likewise, anticoagulant use pre-COVID19 diagnosis was not associated with a decreased risk for allcause mortality, mechanical ventilation, or hospital admission in a study from the New York City health system,
suggesting that previous anticoagulant use did not protect
against development of severe COVID-19 [40]. Also, our
preliminary analysis of the HOPE COVID-19 Registry observed a signiﬁcantly lower survival and higher mortality
risk in COVID-19 patients on OAC therapy at hospital
admission compared to patients without prior OAC at
admission [9]. More recently, a nationwide register-based
cohort study in Sweden demonstrated that ongoing DOAC
use at the time of SARS-CoV-2 infection was not associated
with reduced risk of COVID-19 hospitalization or the
composite of ICU admission or death due to COVID-19,
indicating that the evidence for DOACs in this context is
controversial [41].
Our results in the present study conﬁrm our previous
observation about the higher risk of mortality in COVID-19
patients with OAC therapy before hospital admission. Of
note, our analysis is balanced by PSM, and there were no
diﬀerences regarding admission to the ICU in patients on
prior and no prior OAC. However, not only mortality was
increased in patients with prior OAC therapy but also other
clinical outcomes. Despite an appropriate PSM adjusting for
comorbidities, postadmission serum creatinine as a marker
of renal function (and injury) and troponins as markers of
myocardial damage were higher in these patients, thereby
showing increased rates of heart failure and renal failure
during hospitalization. This reinforces the hypothesis that
OAC-treated patients are particularly vulnerable and still
have an inherent proinﬂammatory state.
4.1. Limitations. We should acknowledge some limitations
in relation to this study. First, the constraints of an observational registry study of this design need to be considered.
Second, the HOPE Registry only included patients from the
ﬁrst wave of the pandemic, and therefore, our results
probably require further investigation during the subsequent
waves. A bias inherent in the ﬁrst wave neither can be
excluded, given that hospitalization services throughout the
world were overwhelmed. We also recognize that including
several diﬀerent indications for OAC may hinder and dissipate the speciﬁc eﬀect that each indication has, since
patients presented diﬀerent risk proﬁles.
In addition, the indication for OAC as a whole may have
some inﬂuence on the risk of outcomes, but comparing
patients with prior OAC and no OAC was actually our aim,
so we cannot adjust for speciﬁc indications for OAC but only
for demographics data and other comorbidities at baseline.
The absence of INR determinations (and therefore the time
in therapeutic range (TTR)) in VKA-treated patients is also a
limitation since the eﬃcacy and safety of VKA depend on the
quality of anticoagulant control, as reﬂected by the average
TTR of INRs 2.0-3.0, and therefore may be related to the risk
of worse outcomes. In addition, the type of DOAC was
unknown in some cases, and this prevented us for analyzing
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drug types as separate. Finally, although this cohort was
collected in a prospective manner, the results reported in this
study are based on a post hoc analysis and should be
regarded as hypothesis-generating.

5. Conclusion
Hospitalized COVID-19 patients on prior OAC therapy had
a higher risk of mortality and worse clinical outcomes
compared to patients without prior OAC therapy, even after
adjusting for comorbidities using PSM. There were no
diﬀerences in clinical outcomes in patients previously taking
VKAs versus DOACs.
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